A Randomized Phase II Study Of Cho(E)P Vs Cc-486-Cho(E)P Vs Duvelisib-Cho(E)P In Previously Untreated Cd30 Negative Peripheral T-Cell Lymphomas
Posted Date: Apr 26, 2024
- Investigator: Tahir Latif
- Specialties: Cancer, Lymphoma
- Type of Study: Drug
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma
Criteria:
Null
Keywords:
Non-Hodgkin, T-Cell Lymphoma, Follicular Lymphoma
For More Information:
Emily Greve
NULL
cancer@uchealth.com